Fulcrum Therapeutics, Inc. (FULC)

NASDAQ: FULC · IEX Real-Time Price · USD
4.87
+0.02 (0.41%)
Jun 29, 2022 11:47 AM EDT - Market open
0.41%
Market Cap 198.93M
Revenue (ttm) 16.97M
Net Income (ttm) -89.78M
Shares Out 40.85M
EPS (ttm) -2.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 135,814
Open 4.84
Previous Close 4.85
Day's Range 4.67 - 4.90
52-Week Range 3.21 - 33.10
Beta 2.54
Analysts Buy
Price Target 28.94 (+494.3%)
Earnings Date Aug 9, 2022

About FULC

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug... [Read more...]

Industry Pharmaceuticals
IPO Date Jul 18, 2019
Employees 104
Stock Exchange NASDAQ
Ticker Symbol FULC
Full Company Profile

Financial Performance

In 2021, FULC's revenue was $19.16 million, an increase of 117.19% compared to the previous year's $8.82 million. Losses were -$80.85 million, 14.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for FULC stock is "Buy." The 12-month stock price forecast is 28.94, which is an increase of 494.25% from the latest price.

Price Target
$28.94
(494.25% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defi...

Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the On...

- Achieved up to 6.3% hemoglobin F (HbF) induction in initial subjects in first cohort; HbF was increasing at last measured timepoint

Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Diseas...

- FTX-6058 is the only oral hemoglobin F (HbF) inducer in clinical development

Fulcrum Therapeutics, Inc. (FULC) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Fulcrum Therapeutics, Inc. (FULC) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agree...

Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Misses Revenue Estimates

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of -1.59% and 24.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results

– In itial data from Phase 1b trial of FTX-6058 in sickle cell disease to be presented at the EHA 2022 Congress –

Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ®  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically de...

After Plunging 59.2% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics, Inc. (FULC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analy...

Earnings Preview: Fulcrum Therapeutics, Inc. (FULC) Q1 Earnings Expected to Decline

Fulcrum Therapeutics, Inc. (FULC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is the Options Market Predicting a Spike in Fulcrum (FULC) Stock?

Investors need to pay close attention to Fulcrum (FULC) stock based on the movements in the options market lately.

Fulcrum Therapeutics, Inc. (FULC) Stock Jumps 5.7%: Will It Continue to Soar?

Fulcrum Therapeutics, Inc. (FULC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the n...

Fulcrum Therapeutics® Announces Multiple Presentations on FSHD at the American Academy of Neurology's Annual Meeting

Presentations highlight potential of losmapimod to slow or stop progression of FSHD

Fulcrum Therapeutics® to Host Virtual Key Opinion Leader Webcast Featuring Losmapimod for Facioscapulohumeral Muscula...

Event to discuss unmet need in FSHD, key measures of disease progression and Phase 3 REACH trial

Fulcrum Therapeutics® Presents Data Highlighting Reachable Workspace (RWS) as Relevant Functional Endpoint in Faciosc...

RWS has been correlated with ability to perform activities of daily living and maintain independence

Does Fulcrum Therapeutics, Inc. (FULC) Have the Potential to Rally 179% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 178.8% in Fulcrum Therapeutics, Inc. (FULC). While the effectiveness of this highly sought-after metric is questi...

Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 10.77% and 26.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s...

Fulcrum Therapeutics® Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results

– Clear path forward for Phase 3 REACH trial with losmapimod in FSHD; Trial expected to begin in 2Q 2022 –

Fulcrum Therapeutics Latest Report On Its Sickle Cell Disease Trials

The Phase 1b trial for the drug remains on track and will be initiated soon.

Fulcrum Therapeutics Shares Additional Data From Phase 1 Trial Of Sickle Cell Disease Treatment

Fulcrum Therapeutics Inc (NASDAQ: FULC) has announced results from the 20mg and 30mg dose cohorts in healthy adult volunteers in its Phase 1 trial of FTX-6058 for sickle cell disease and other hemoglobi...

Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically def...

Fulcrum Therapeutics, Inc. (FULC) Reports Q3 Loss, Tops Revenue Estimates

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 10.94% and 68.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the ...

Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results

–On-track to initiate enrollment by year-end in Phase 1b clinical trial of FTX-6058 in people with sickle cell disease–

Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences

CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically def...

Fulcrum Therapeutics™ to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Thursday, November ...

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically def...

Can Fulcrum Therapeutics, Inc. (FULC) Climb 31% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 30.9% upside potential for Fulcrum Therapeutics, Inc. (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e...